Erythrocyte membrane fluidity during mesoglycan treatment

Abstract

In a group of 10 subjects with vascular atherosclerotic disease (VAD) and in a group of 15 VAD subjects with non-insulin-dependent diabetes mellitus (NIDDM), treated in monotherapy with mesoglycan, we examined, at baseline and after 30 days the erythrocyte membrane fluidity. From the obtained results, it is evident that in both groups the treatment with mesoglycan is responsible for an increase of this microrheological parameter.